

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/021,126-Conf. #7268	
			Filing Date	December 12, 2001	
			First Named Inventor	Connie Sanchez	
			Art Unit	1614	
			Examiner Name	F. Krass	
Sheet	1	of	1	Attorney Docket Number	05432/000J951-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
FK	CA /	P. Auquier et al., <i>Int. J. Psychiatr. Clin. Pract.</i> 7:259-268 (2003)			
FK	CB /	E. Bien et al., <i>Behav. Pharmacol.</i> 14:S37 (2003)			
FK	CC	E. W. Fish et al., <i>J. Pharmacol. Exp. Ther.</i> October 30, 2003, Fast Forward publ. as DOI: 10.1124/jpet.103.058206 (2004)			
FK	CD	C. Sanchez et al., <i>Psychopharmacology</i> 167:353-362 (2003)			
FK	CE /	C. Sanchez, <i>Behav. Pharmacol.</i> 14:465-470 (2003)			
FK	CF /	C. Sanchez et al. <i>Psychopharmacology (Berl.)</i> (2004), "Escitalopram versus citalopram: the surprising role of the R-enantiomer"			
FK	CG	Declaration of Connie Sanchez. (2005)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The PTO did not receive the following
listed item(s) cite # CC

W:1054 2210001	Krass, Frederick	Date Considered	3-24-05
-------------------	------------------	--------------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/021,126-Conf. #7268
				Filing Date	December 12, 2001
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	F. F. Krass
Sheet	1	of	2	Attorney Docket Number	05432/000J951-US0


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
FK	1	US-2002/0103249-A1	08-01-2002	H. Lundbeck A/S	
FK	2	US- 6,169,105-B1	01-2001	Wong et al.	
FK	3	US- 6,184,219-B1	02-2001	Evenden et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
FK	4	EP-0 347 066 A1	12-20-1989	H. Lundbeck A/S		
FK	5	WO-01/03694 A1	01-18-2001	H. Lundbeck A/S		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
FK	6	Sackeim, H.A., The definition and meaning of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 10-17			
FK	7	Willner, P., Psychopharmacology, 1997, 134, 319-329			
FK	8	Nierenber, A.A and DeCecco, L.M., Definitions of antidepressant treatment response, remission, non-response, partial response, and other relevant outcomes: A focus on treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 5-9			
FK	9	Kornstein, S.C. and Schneider, R.K., Clinical features of treatment-resistant depression, J. Clin. Psychiatr 2001, 62 Suppl 16, 18-25			
FK	10	Poster, "Escitalopram and Paroxetine in Fixed Doses for the Treatment of Social Anxiety Disorder (SAD), Presented at the 44th Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology, 9-12 April 2003, Juan-les-Pins, France, 1 page.			
FK	11	Kasper, Siegfried, et al., "Escitalopram is Efficacious and well Tolerated in Treatment of Social Anxiety Disorder", ADAA National Conference, 21-24 March 2002, 1 page.			
FK	12	Davidson, Jonathan, et al., "Escitalopram in the Treatment of Generalized Anxiety Disorder", Presented at the 22nd National Conference of the Anxiety Disorder Association of America, March 21-24, 2002, Austin, Texas, NR57, 1 page.			
FK	13	Stahl, Stephen, et al., "Escitalopram in the Treatment of Panic Disorder", Presented at the 22nd National Conference of the Anxiety Disorders Association of America, March 21-24, 2002, Austin, Texas, NR56, 1 page.			
FK	14	Lader, Malcolm, et al., "Efficacy and Tolerability of Escitalopram in 12- and 24-Week Treatment of Social Anxiety Disorder: Randomised, Double-Blind, Placebo-Controlled, Fixed-Dose Study", Depression and Anxiety, 19: 241-248 (2004).			
FK	15	Huffman, Jeff C., et al., "The Development of New Antidepressants: Focus on Duloxetine and Escitalopram", Harv Rev Psychiatry, 11:30-36 (2003).			
FK	16	Waugh, John, et al., "Escitalopram, A review of its Use in the Management of Major			

Examiner Signature	Krass, Frederick	Date Considered	3-24-05
--------------------	------------------	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	05432/000J951-US0
-------	---	----	---	------------------------	-------------------

Complete if Known

Application Number	10/021,126-Conf. #7268
Filing Date	December 12, 2001
First Named Inventor	Connie Sanchez
Art Unit	1614
Examiner Name	F. F. Krass

PR		Depressive and Anxiety Disorders", CNS Drugs, 17 (5): 343-362 (2003).	
PR	17	Burke, William J., "Escitalopram", Expert Opin. Investig. Drugs, 11(10): 1477-1486 (2002).	
PR	18	Farah, Andrew, "Therapeutic Advantages of Escitalopram in Depression and Anxiety Disorders", Primary Psychiatry, 9(12): 30-35 (2002).	
PR	19	Montgomery, S.A., et al., "The antidepressant efficacy of citalopram", International Clinical Psychopharmacology (1996), Vol. 11, Supplement 1, pp. 29-33.	
PR	20	Bouchard, J.M., et al., "Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion: A double-blind comparative trial", Journal of Affective Disorders, Vol. 46, pp. 51-58 (1997).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Krass, Frederick	Date Considered	3-24-05
-----------------------	------------------	--------------------	---------